What is Vertex Pharmaceuticals's revenue?

Vertex Pharmaceuticals (VRTX) generated $12.2B in revenue over the trailing twelve months, up 10.1% year over year.

Is Vertex Pharmaceuticals profitable?

Vertex Pharmaceuticals reported $4.3B in net income over the trailing twelve months, a 35.5% net margin.

What are Vertex Pharmaceuticals's profit margins?

Gross margin is 86.2% and operating margin is 38.3%, with a 35.5% net margin.

What is Vertex Pharmaceuticals's earnings per share?

Vertex Pharmaceuticals's diluted EPS over the trailing twelve months is $16.85.

Where does Vertex Pharmaceuticals's income statement data come from?

Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Vertex Pharmaceuticals VRTX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$2.99B+7.8%	$3.19B+9.5%	$3.08B+11.0%	$2.96B+12.1%	$2.77B+3.0%
Total cost of revenue	$392.8M+8.2%	$466M+10.1%	$414.8M+5.7%	$407.5M+9.6%	$363M+6.0%
Gross profit	$2.59B+7.8%	$2.72B+9.5%	$2.66B+11.9%	$2.56B+12.5%	$2.41B+2.5%
Gross margin	86.8%0.0pp	85.4%-0.1pp	86.5%+0.7pp	86.3%+0.3pp	86.9%-0.4pp
Selling, general and administrative	$493.7M+24.5%	$487M+29.0%	$445.1M+19.7%	$424.6M+14.1%	$396.4M+15.7%
Occupancy and equipment	——	$48.68M+87.4%	$48.68M+87.4%	$48.68M+87.4%	$48.68M+87.4%
Depreciation and amortization	$55.9M+15.5%	$55.7M+19.8%	$54M+1.5%	$51.7M-4.3%	$48.4M-9.5%
Other operating expenses	——	$200K—	$200K—	$200K—	$200K—
Total costs & expenses	$1.85B-13.6%	$1.98B+5.2%	$1.89B+14.2%	$1.81B-70.6%	$2.14B+38.0%
Operating income	$1.14B+80.6%	$1.21B—	$1.19B+6.3%	$1.15B+133%	$630.1M-44.7%
Operating margin	38.1%+15.4pp	37.8%—	38.6%-1.7pp	38.8%+172pp	22.7%-19.6pp
Income before income taxes	$1.25B+71.5%	$1.33B+17.1%	$1.3B+6.1%	$1.28B+138%	$730.4M-42.9%
Income tax expense	$221.5M+163%	$139.9M-37.4%	$215.9M+20.8%	$250.1M+23.6%	$84.1M-53.1%
Net income	$1.03B+59.6%	$1.19B—	$1.08B+3.6%	$1.03B+129%	$646.3M-41.2%
Net margin	34.5%+11.2pp	37.3%—	35.2%-2.5pp	34.8%+171pp	23.3%-17.5pp
Diluted earnings per share	$4.02+61.4%	$4.64—	$4.20+4.7%	$3.99+129%	$2.49-40.9%
Basic earnings per share	$4.06+61.1%	$4.69—	$4.24+4.7%	$4.02+129%	$2.52-40.8%
Weighted-average shares, diluted	256.3M-1.2%	258M0.0%	257.6M-1.3%	258.9M+0.3%	259.5M-0.6%
Weighted-average shares, basic	254.1M-1.1%	255.7M-0.9%	255.6M-0.9%	256.7M-0.5%	256.9M-0.5%
Advertising costs	——	$50.7M+137%	$50.7M+137%	$50.7M+137%	$50.7M+137%
Amortization of capitalized software and acquired intangible assets	——	$5.05M0.0%	$5.05M0.0%	$5.05M0.0%	$5.05M0.0%
Software amortization expense	——	$7.8M+23.8%	$7.8M+23.8%	$7.8M+23.8%	$7.8M+23.8%
Common stock, number of votes per share	——	$0.25—	$0.25—	$0.25—	$0.25—
Federal	——	$169.78M-3.7%	$169.78M-3.7%	$169.78M-3.7%	$169.78M-3.7%
Foreign	——	$121.45M+56.8%	$121.45M+56.8%	$121.45M+56.8%	$121.45M+56.8%
Current State And Local Tax Expense Benefit	——	$8.98M-69.6%	$8.98M-69.6%	$8.98M-69.6%	$8.98M-69.6%
Federal	——	-$131.75M-20.1%	-$131.75M-20.1%	-$131.75M-20.1%	-$131.75M-20.1%
Deferred Foreign Income Tax Expense Benefit	——	$9.58M-72.4%	$9.58M-72.4%	$9.58M-72.4%	$9.58M-72.4%
Deferred taxes	——	-$127.7M-46.4%	-$127.7M-46.4%	-$127.7M-46.4%	-$127.7M-46.4%
State	——	-$5.53M+54.6%	-$5.53M+54.6%	-$5.53M+54.6%	-$5.53M+54.6%
Defined Contribution Plan Cost Recognized	——	$15.78M+20.7%	$15.78M+20.7%	$15.78M+20.7%	$15.78M+20.7%
Maximum percentage of annual compensation contributed by the participant (percent)	——	60%—	——	——	——
Depreciation	——	$38.95M-2.9%	$38.95M-2.9%	$38.95M-2.9%	$38.95M-2.9%
Income taxes at U.S. statutory rate of 21%	——	$0.050.0%	$0.050.0%	$0.050.0%	$0.050.0%
Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount	——	$200K—	$200K—	$200K—	$200K—
Subpart F income, net of credits	——	-2.1%—	——	——	——
Subpart F income, net of credits	——	-$24.35M—	-$24.35M—	-$24.35M—	-$24.35M—
Other	——	0%—	——	——	——
Deferred charges related to intra-entity transfers	——	-$15.38M—	-$15.38M—	-$15.38M—	-$15.38M—
Deferred charges related to intra-entity transfers	——	-1.3%—	——	——	——
Effective Income Tax Rate Reconciliation, FDII, Amount	——	$14.63M—	$14.63M—	$14.63M—	$14.63M—
Effective Income Tax Rate Reconciliation, FDII, Percent	——	1.3%-27.0%	——	——	——
Foreign operations	——	——	——	——	——
Non-deductible AIPR&D	——	——	——	——	——
Other	——	$0—	$0—	$0—	$0—
U.S. tax on foreign earnings, net of credits	——	——	——	——	——
State income taxes – net of federal income tax benefit	——	$0-100%	$0-100%	$0-100%	$0-100%
Changes in unrecognized tax benefits	——	1.4%-9.9%	——	——	——
Finance Lease Right Of Use Asset Amortization	——	$1.8M-76.7%	$1.8M-76.7%	$1.8M-76.7%	$1.8M-76.7%
Gain (Loss), Foreign Currency Transaction, before Tax	——	-$3.43M+49.8%	-$3.43M+49.8%	-$3.43M+49.8%	-$3.43M+49.8%
Income Loss From Continuing Operations Before Income Taxes Domestic	——	$705.3M+306%	$705.3M+306%	$705.3M+306%	$705.3M+306%
Income Loss From Continuing Operations Before Income Taxes Foreign	——	$455.5M+12.6%	$455.5M+12.6%	$455.5M+12.6%	$455.5M+12.6%
Federal taxes	——	$242.23M—	$242.23M—	$242.23M—	$242.23M—
State taxes	——	$18.55M—	$18.55M—	$18.55M—	$18.55M—
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	$243.78M—	$243.78M—	$243.78M—	$243.78M—
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$6.35M—	$6.35M—	$6.35M—	$6.35M—
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	-$475K—	-$475K—	-$475K—	-$475K—
Changes in unrecognized tax benefits	——	$16.08M—	$16.08M—	$16.08M—	$16.08M—
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$38.6M—	$38.6M—	$38.6M—	$38.6M—
Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount	——	$15.48M—	$15.48M—	$15.48M—	$15.48M—
Income Taxes Paid, Net	$82.3M-55.4%	$389.4M+43.3%	$479.6M+72.2%	$513.3M+3.3%	$184.4M+430%
Accounts payable	$35.6M+35.9%	$38.3M+356%	-$35.3M-153%	$7.6M+130%	$26.2M+26,100%
Increase (Decrease) in Accounts Receivable	-$39.8M-123%	$99.4M—	$59.9M+15.6%	$18.4M—	$169.6M-32.6%
Increase in accrued expenses and other liabilities	$70.5M+46.6%	-$664.5M—	$332.9M+95.1%	$166.6M-1.0%	$48.1M-75.2%
Increase (Decrease) in Inventories	$97.7M-41.5%	$77.4M-47.5%	$131.1M-28.2%	$148.6M+38.6%	$167.1M+109%
Other liabilities	$23.1M+5.0%	$105.8M—	$83.9M-37.4%	-$63.2M+75.4%	$22M-86.9%
Increase (Decrease) in Prepaid Expense and Other Assets	-$173.4M-717%	$250.6M+52.2%	$40.9M—	$76.4M-51.0%	$28.1M+128%
Interest Paid, Excluding Capitalized Interest, Operating Activity	$3.2M+18.5%	$3M+11.1%	$3.2M-60.5%	$3.5M-63.9%	$2.7M-73.0%
Net interest and investment income (loss)	$114.8M-2.6%	——	——	——	$117.9M—
Lease Cost	——	$64.38M+27.5%	$64.38M+27.5%	$64.38M+27.5%	$64.38M+27.5%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$538.8M+20.8%	-$77.2M+80.3%	-$1.15B-198%	-$349.2M+2.6%	-$680.4M-90.3%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$431.9M-674%	-$288.1M+64.9%	-$117M+66.4%	-$484.5M-4.5%	-$55.8M+97.4%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$1.43B+74.4%	$498M+504%	$1.24B+1,108%	$1.07B+971%	$818.9M+765%
Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets	——	$0—	$0—	$0—	$0—
Operating Lease Payments	——	$45.8M+61.4%	$45.8M+61.4%	$45.8M+61.4%	$45.8M+61.4%
Other Noncash Income (Expense)	$5M+113%	-$23.1M-40.9%	$0+100%	-$57.8M-379%	-$39.2M-208%
Other income, net (Note 6)	$0+100%	——	-$9.8M+42.0%	$13.2M+157%	-$17.6M+43.6%
Payment for (Proceeds from) Other Investing Activity	$0-100%	$15.9M-48.5%	$0-100%	$4.3M-71.3%	$5.3M—
Payments for Repurchase of Common Stock	$336.9M-20.9%	$128.4M-69.3%	$1.07B+248%	$391.8M+22.3%	$426.1M+225%
Payment, Tax Withholding, Share-Based Payment Arrangement	$228.5M-15.5%	$2.5M-65.8%	$91M+8.7%	$5.9M-92.7%	$270.5M+15.8%
Payments to Acquire Debt Securities, Available-for-Sale	$2.51B+52.2%	$1.23B-43.0%	$1.35B-2.8%	$2.17B+67.6%	$1.65B-36.6%
Payments to Acquire Property, Plant, and Equipment	$133.4M+228%	$149.4M+61.3%	$101.8M+50.4%	$145.7M+111%	$40.7M-40.5%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	$27M+61.7%	$54M+57.4%	$7.9M-6.0%	$49.1M-10.7%	$16.7M-1.2%
Financing — other	-$400K+20.0%	$1.1M+22.2%	$1.1M+22.2%	$2M+122%	-$500K-114%
Proceeds from sales and redemptions of investments in debt securities classified as available for sale	$2.21B+34.9%	$1.09B-25.2%	$1.33B+19.5%	$1.84B+55.5%	$1.64B+130%
Cash received from option exercises	——	$13.9M+11.2%	$13.9M+11.2%	$13.9M+11.2%	$13.9M+11.2%
Property, Plant and Equipment, Gross, Period Increase (Decrease)	——	-$26.88M—	-$26.88M—	-$26.88M—	-$26.88M—
Reduction to finance leases	——	$68.83M—	$68.83M—	$68.83M—	$68.83M—
Research and development expense	$961.6M-1.8%	$973.7M-2.5%	$977.7M+11.6%	$978.4M+1.2%	$979.7M+24.2%
Revenue From Contract With Customer Excluding Assessed Tax	$2.99B+7.8%	$3.19B+9.5%	$3.08B+11.0%	$2.96B+12.1%	$2.77B+3.0%
Stock-based compensation	$166.4M+0.2%	$157.6M-6.1%	$194.9M+5.6%	$167.3M+8.5%	$166.1M-13.4%
Granted (in shares)	——	7K—	——	——	——
Intrinsic value of stock options exercised	——	$36.95M+31.0%	$36.95M+31.0%	$36.95M+31.0%	$36.95M+31.0%
Granted (in shares)	——	$502.97—	——	——	——
Exercised (in shares)	——	$125.30—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	——	447K—	——	——	——
Stock Repurchased During Period Shares	——	$1.2M+77.8%	$1.2M+77.8%	$1.2M+77.8%	$1.2M+77.8%
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions	——	$1.43M+200%	$1.43M+200%	$1.43M+200%	$1.43M+200%
Unrecognized tax benefits, settlements	——	$1.58M-56.6%	$1.58M-56.6%	$1.58M-56.6%	$1.58M-56.6%
Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation	——	——	——	——	——
Unrecognized tax benefits, deferred tax liabilities, gross	——	$34.63M+50.7%	$34.63M+50.7%	$34.63M+50.7%	$34.63M+50.7%
Interest expense and penalties, net (benefit)/charge recognized	——	$3.28M+132%	$3.28M+132%	$3.28M+132%	$3.28M+132%
Unrecognized tax benefits, increase (decrease) in deferred tax assets, gross	——	-$1.85M-563%	-$1.85M-563%	-$1.85M-563%	-$1.85M-563%
Foreign currency effect	——	$10.98M—	$10.98M—	$10.98M—	$10.98M—
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions	——	$29.88M+0.3%	$29.88M+0.3%	$29.88M+0.3%	$29.88M+0.3%
Additions for tax positions of prior years	——	$1.3M+13.0%	$1.3M+13.0%	$1.3M+13.0%	$1.3M+13.0%
Increase (decrease) in amount of unrecognized tax benefits	——	$36.48M+61.6%	$36.48M+61.6%	$36.48M+61.6%	$36.48M+61.6%
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations	——	$2.68M-35.5%	$2.68M-35.5%	$2.68M-35.5%	$2.68M-35.5%
Variable Lease Cost	——	$12.53M+14.9%	$12.53M+14.9%	$12.53M+14.9%	$12.53M+14.9%
EBITDA	$1.19B+76.0%	$1.26B+6.4%	$1.24B+6.0%	$1.2B+135%	$678.5M-43.1%
EBITDA margin	40%+15.5pp	39.5%-1.2pp	40.3%-1.9pp	40.6%+171pp	24.5%-19.8pp
EBIT	$1.14B+80.6%	$1.21B+5.8%	$1.19B+6.3%	$1.15B+133%	$630.1M-44.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Vertex Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vertex Pharmaceuticals's revenue?: Vertex Pharmaceuticals (VRTX) generated $12.2B in revenue over the trailing twelve months, up 10.1% year over year.
Is Vertex Pharmaceuticals profitable?: Vertex Pharmaceuticals reported $4.3B in net income over the trailing twelve months, a 35.5% net margin.
What are Vertex Pharmaceuticals's profit margins?: Gross margin is 86.2% and operating margin is 38.3%, with a 35.5% net margin.
What is Vertex Pharmaceuticals's earnings per share?: Vertex Pharmaceuticals's diluted EPS over the trailing twelve months is $16.85.
Where does Vertex Pharmaceuticals's income statement data come from?: Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.